This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
Blutspendezentrum SRK beider Basel, University Hospital Basel
Basel, Switzerland
Serious adverse events in convalescent plasma treated patients
Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infection
Time frame: From baseline (enrolment) to 24 hours follow-up
Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients
Change in SARS-CoV2 quantitative in nasopharyngeal swab
Time frame: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Transfer to ICU
Transfer to ICU
Time frame: at Baseline (admission to Covid-ward) until day 28
in-hospital death
in-hospital death
Time frame: at Baseline (admission to Covid-ward) until day 28
Virologic clearance in plasma of convalescent plasma treated patients
Change in SARS-CoV2 quantitative in plasma
Time frame: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Time to discharge from hospital after enrolment
Duration of hospitalisation
Time frame: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)
Humoral immune response
Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)
Time frame: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.